×
About 182,670 results

Lower bevacizumab doses, agents with less systemic exposure may be safer options for ROP
https://www.healio.com/news/ophthalmology/20220203/lower-bevacizumab-doses-agents-with-less-systemic-exposure-may-be-safer-options-for-rop

Feb 3rd, 2022 - WAIKOLOA, Hawaii — Systemic effects of anti-VEGF in retinopathy of prematurity have not been ruled out, so it may be wise to use bevacizumab in lower doses or switch to agents with less systemic exposure, according to one presenter. “The BEAT-ROP study demonstrated a beneficial effect for bevacizumab vs. laser in the treatment of zone I, stage 3+ ROP. But one thing I didn’t like was the complet...

Remission From Type 2 Diabetes: Myth or Reality?
https://www.medscape.com/viewarticle/985111

Dec 6th, 2022 - Stockholm, Sweden — Because half of patients with type 2 diabetes (T2D) in France have blood glucose levels that are outside of their target range, the idea of remission from the condition is not at the forefront of doctors' minds. It takes second place to glycemic control. Yet, an international consensus suggests that modern-day medicines now make remission possible in those recently diagnosed...

Retreatment with anti-tumor necrosis factor therapy in combination with an immunomodula...
https://doi.org/10.1097/MEG.0000000000002474
European Journal of Gastroenterology & Hepatology; Ten Bokkel Huinink S, Beelen EMJ et. al.

Dec 6th, 2022 - A considerable proportion of Crohn's disease patients that undergo ileocecal resection (ICR) have failed anti-tumor necrosis factor (TNF) therapy preoperatively. This study aimed to assess the effectiveness of retreatment of anti-TNF therapy in patients with postoperative recurrence. A real-world cohort study was performed on Crohn's disease patients who underwent primary ICR after anti-TNF the...

A novel tumor-promoting role for nuclear factor IX in glioblastoma is mediated through ...
https://doi.org/10.1158/1541-7786.MCR-22-0504
Molecular Cancer Research : MCR; Ge R, Wang C et. al.

Dec 6th, 2022 - Our previous study illustrated that nuclear factor IX (NFIX) promotes glioblastoma (GBM) progression by inducing migration and proliferation of GBM cells. However, the underlying mechanism of how NFIX regulates GBM cell proliferation remains obscure. In this study, we uncovered that Go-Ichi-Ni-San 1 (GINS1) is up-regulated and positively correlated with NFIX in human GBM specimen. NFIX silencin...

The state-of-the-art pharmacotherapeutic management of neovascular age-related macular ...
https://doi.org/10.1080/14656566.2022.2154145
Expert Opinion on Pharmacotherapy; Servillo A, Zucchiatti I et. al.

Dec 6th, 2022 - Age-related macular degeneration (AMD) is a major cause of central visual loss in the developed world. Although the pathogenesis is not fully understood, vascular endothelial growth factor (VEGF) is considered the most important growth factor involved in angiogenesis and exudation in neovascular AMD eyes. Advances in anti-VEGF agents have changed the treatment approach for wet AMD, allowing bet...

A new series of thiazole-hydrazone hybrids for Akt-targeted therapy of non-small cell l...
https://doi.org/10.1002/ddr.22022
Drug Development Research; Orujova T, Ece A et. al.

Dec 6th, 2022 - In an attempt to identify potent antitumor agents for the fight against non-small cell lung cancer, new thiazolyl hydrazones (2a-n) were synthesized and examined for their in vitro cytotoxic effects on A549 human lung adenocarcinoma and L929 mouse embryonic fibroblast cells by means of the MTT assay. Furthermore, the effects of the most potent anticancer agents on apoptosis and Akt inhibition w...

Adverse events associated with intra-arterial administration of gadolinium-based contra...
https://doi.org/10.1016/j.jvir.2022.11.022
Journal of Vascular and Interventional Radiology : JVIR; MacLeod CA, Gauthier I et. al.

Dec 5th, 2022 - To determine the risk of immediate hypersensitivity reactions (HRs), contrast-associated acute kidney injury (CA-AKI), nephrogenic systemic fibrosis (NSF), and gadolinium retention associated with use of intra-arterial gadolinium-based contrast agents (GBCA). MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from 1988 (GBCA approved for clinical use) to...

Posterior reversible encephalopathy syndrome and autoimmunity.
https://doi.org/10.1016/j.autrev.2022.103239
Autoimmunity Reviews; Li Y, Song J et. al.

Dec 5th, 2022 - Posterior reversible encephalopathy syndrome (PRES) is a clinical syndrome characterized by acute or subacute onset of neurological symptoms (e.g., headache, seizure, confusion, vomiting, and diminished eyesight) and impaired endothelial barrier function of the cerebral circulation that leads to bilateral subcortical vasogenic edema, while exhibiting a "reversible" feature in most cases. Clinic...

Detection of parasite-derived tRNA and rRNA fragments in the peripheral blood of mice e...
https://doi.org/10.1016/j.parint.2022.102716
Parasitology International; Kusakisako K, Nakao R et. al.

Dec 5th, 2022 - All prokaryotes and eukaryotes, including parasites, release extracellular vesicles or exosomes that contain selected proteins, lipids, nucleic acids, glycoconjugates, and metabolites. Leishmania exosomes are highly enriched in small RNAs derived from the rRNAs and tRNAs of the protozoan parasite species. Here, using plasma exosomes isolated by a kit and next-generation sequencing, we report th...

The emerging therapeutic landscape of relapsed/refractory multiple myeloma.
https://doi.org/10.1007/s00277-022-05058-5
Annals of Hematology; Tanenbaum B, Miett T et. al.

Dec 4th, 2022 - From a historic lens, treatment for patients with relapsed/refractory multiple myeloma (R/R MM) has advanced significantly since the advent of immunomodulatory agents (IMiDs) in the 1990s, proteasome inhibitors in the 2000s, monoclonal antibodies in the 2010s, and CAR-T treatments in the 2020s. However, the availability of multiple new therapies has also created significant ambiguity regarding ...

High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1...
https://doi.org/10.1016/j.canlet.2022.216028
Cancer Letters; Grissenberger S, Sturtzel C et. al.

Dec 4th, 2022 - Ewing sarcoma is a pediatric bone and soft tissue cancer with an urgent need for new therapies to improve disease outcome. To identify effective drugs, phenotypic drug screening has proven to be a powerful method, but achievable throughput in mouse xenografts, the preclinical Ewing sarcoma standard model, is limited. Here, we explored the use of xenografts in zebrafish for high-throughput drug ...

Activation of cannabinoid-2 receptor protects against Pseudomonas aeruginosa induced ac...
https://doi.org/10.1186/s12931-022-02253-w
Respiratory Research; Nagre N, Nicholson G et. al.

Dec 4th, 2022 - Bacterial pneumonia is a major risk factor for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Pseudomonas aeruginosa (PA), an opportunistic pathogen with an increasing resistance acquired against multiple drugs, is one of the main causative agents of ALI and ARDS in diverse clinical settings. Given the anti-inflammatory role of the cannabinoid-2 receptor (CB2R), the eff...

Optimizing targeted drug selection in combination therapy for patients with advanced or...
https://doi.org/10.1002/cam4.5504
Cancer Medicine; Xie R, Wu J et. al.

Dec 3rd, 2022 - For patients with advanced or metastatic renal cell carcinoma (RCC), the dose of targeted agents was recommended in combination with immune checkpoint inhibitors. We performed a network meta-analysis to describe a categorized safety ranking profile and assess the adaptability of the combination options of targeted agents. The targeted agents refer to vascular endothelial growth factor tyrosine ...

A retrospective study of cladribine and low-dose cytarabine-based regimens for the trea...
https://doi.org/10.1002/cncr.34564
Cancer Bazinet A, Darbaniyan F et. al.

Dec 3rd, 2022 - Patients with higher risk chronic myelomonocytic leukemia (CMML) have limited therapeutic options beyond hydroxyurea and hypomethylating agents (HMAs). Regimens based on a backbone of cladribine (CLAD), low-dose cytarabine (LDAC), and an HMA are effective low-intensity therapies for acute myeloid leukemia (AML). The authors conducted a retrospective chart review to evaluate the efficacy of CLAD...

Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endotheli...
https://doi.org/10.1007/s10456-022-09863-4
Angiogenesis Nowak-Sliwinska P, van Beijnum JR et. al.

Dec 3rd, 2022 - Ongoing angiogenesis renders the tumor endothelium unresponsive to inflammatory cytokines and interferes with adhesion of leukocytes, resulting in escape from immunity. This process is referred to as tumor endothelial cell anergy. We aimed to investigate whether anti-angiogenic agents can overcome endothelial cell anergy and provide pro-inflammatory conditions. Tissues of renal cell carcinoma (...

Risk of melanoma and nonmelanoma skin cancer with immunosuppressants Part I: Calcineuri...
https://doi.org/10.1016/j.jaad.2022.11.044
Journal of the American Academy of Dermatology; Kreher MA, Noland MMB et. al.

Dec 3rd, 2022 - Immunosuppression is a well-documented risk factor for skin cancer, as exemplified by the 65 to 250-fold higher squamous cell carcinoma risk, 10-fold higher basal cell carcinoma risk, and 0 to 8-fold higher melanoma risk in solid organ transplant recipients (SOTRs) receiving potent, prolonged courses of immunosuppressive therapies. Numerous immune system components have been shown to either sup...

Durable medication-free remission of sarcoidosis following discontinuation of anti-tumo...
https://doi.org/10.1016/j.rmed.2022.107055
Respiratory Medicine; Yee AMF

Dec 3rd, 2022 - Monoclonal antibodies against tumor necrosis factor-alpha (TNF-α) have been used successfully in the treatment of sarcoidosis, but optimal duration of their use is unclear. Published studies have consistently suggested that withdrawal of therapy typically results in prompt disease relapse. The aim of this study is to identify and characterize patients with sarcoidosis in whom medication-free di...

Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed...
https://doi.org/10.1007/s00277-022-05056-7
Annals of Hematology; Kang Y, Sundaramoorthy P et. al.

Dec 3rd, 2022 - Multiple myeloma (MM) remains an incurable disease and there is an unmet medical need for novel therapeutic drugs that do not share similar mechanisms of action with currently available agents. Sphingosine kinase 2 (SK2) is an innovative molecular target for anticancer therapy. We previously reported that treatment with SK2 inhibitor opaganib inhibited myeloma tumor growth in vitro and in vivo ...

Cancer screening and prevention education in standardized training residents: A cross-s...
https://doi.org/10.1186/s12909-022-03876-9
BMC Medical Education; Ran J, Dai Z et. al.

Dec 3rd, 2022 - Standardized residency training is an essential aspect of enhancing the ability of cancer prevention and screening of residents. The current study was performed to investigate tumor prevention, screening literacy and the training demands of standardized training residents and explore related influencing factors. A cross-sectional survey was conducted among 320 residents of The First Hospital of...

Targeting integrated stress response with ISRIB combined with imatinib treatment attenu...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719211
BMC Cancer; Dudka W, Hoser G et. al.

Dec 3rd, 2022 - The integrated stress response (ISR) facilitates cellular adaptation to unfavorable conditions by reprogramming the cellular response. ISR activation was reported in neurological disorders and solid tumors; however, the function of ISR and its role as a possible therapeutic target in hematological malignancies still remain largely unexplored. Previously, we showed that the ISR is activated in c...